Navigation Links
Watson Announces Approval of Nulecit™, the First Generic Alternative to Ferrlecit® for the Treatment of Iron Deficiency Anemia
Date:3/31/2011

MORRISTOWN, N.J., March 31, 2011 /PRNewswire/ -- Watson Pharmaceuticals, Inc. (NYSE: WPI) today announced that it is initiating launch activities of Nulecit™ (sodium ferric gluconate complex in sucrose injection), following FDA approval of GeneraMedix Inc.'s, Abbreviated New Drug Application (ANDA).  Nulecit is the first bioequivalent and therapeutically equivalent alternative to Sanofi-Aventis' Ferrlecit®.  In July 2009 Watson signed a license agreement with GeneraMedix for the exclusive U.S. marketing rights to the product, which will be marketed by Watson's Global Brands business.

Nulecit is approved for the treatment of iron deficiency anemia in adults and children age six years or older undergoing chronic hemodialysis who are receiving supplemental epoetin therapy.  It will offer the convenience and cost savings of administration from a single-dose glass vial, minimizing the need for filter needles or a required test dose.

The branded alternative to Nulecit is currently available only in 5 mL glass ampules that require the tops to be broken off manually before administration, and many protocols require that the product withdrawn with a syringe using a filter needle.

"Watson's Brand sales team is uniquely positioned to effectively maximize the opportunities of this value brand offering, given our experience in marketing injectable iron products," said Fred Wilkinson, Executive Vice President, Global Brands, at Watson.  "Nulecit offers the nephrology community a value brand that is bioequivalent to the innovator product, with the added convenience of packaging in glass vials."

Efficacy with Added ConvenienceIn the bioequivalence study, which involved 240 healthy volunteers, Nulecit and Ferrlecit showed comparable concentrations of total serum iron and transferrin-bound iron over 36 hours.  Each 5 mL gla
'/>"/>

SOURCE Watson Pharmaceuticals, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related medicine technology :

1. Watson Confirms Favorable Appeals Court Ruling on Generic SEASONIQUE® Patent Challenge
2. Watson Confirms OxyContin® Patent Challenge
3. Watson Confirms District Court Ruling in Generic Fentora® Patent Suit
4. Cephalon Wins FENTORA Patent Suit Against Watson
5. Watson Launches Generic Famvir®
6. Heygood, Orr & Pearson: Los Angeles Court Orders Watson Pharmaceuticals to Produce Documents, Provide Depositions in Fentanyl Patch Death Lawsuit
7. Watson Announces Favorable District Court Ruling in Generic Fentora® Patent Suit
8. Watson Promotes David Buchen, R. Todd Joyce to Executive Vice President
9. Watson to Present at the Barclays 2011 Global Healthcare Conference
10. Watson to Present at the Cowen & Company 31st Annual Healthcare Conference
11. Watson to Present at the 2011 Citi Global Healthcare Conference
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/24/2014)... , Deutschland, und MARSEILLE ... -- , Weltweite ... ermöglicht QIAGEN die Entwicklung von Tests ... für Blutkrebs  Neuer Test weist ... mit Knochenmarkserkrankungen (myelodysplastischen Syndromen) einen günstigen Krankheitsverlauf ...
(Date:7/24/2014)... CITY, Calif., July 24, 2014  Abaxis, Inc. (NasdaqGS: ... point-of-care blood analysis systems, today reported financial results for ... First quarter overview: , Revenues of $47.5 ... , Diluted EPS of $0.21, up 50% over last ... Medical market revenues of $7.2 million, up 20% over ...
(Date:7/24/2014)... 2014 Amgen (NASDAQ: AMGN ) today ... on Tuesday, July 29, 2014, after the close of the ... conference call with the investment community at 2 p.m. PT. ... A. Bradway , chairman and chief executive officer, and other ... of the conference call will be simultaneously broadcast over the ...
Breaking Medicine Technology:QIAGEN erweitert Pipeline für die personalisierte Medizin um vielversprechende genomische Biomarker zur Prognosebestimmung bei Blutkrebsbehandlungen 2QIAGEN erweitert Pipeline für die personalisierte Medizin um vielversprechende genomische Biomarker zur Prognosebestimmung bei Blutkrebsbehandlungen 3QIAGEN erweitert Pipeline für die personalisierte Medizin um vielversprechende genomische Biomarker zur Prognosebestimmung bei Blutkrebsbehandlungen 4QIAGEN erweitert Pipeline für die personalisierte Medizin um vielversprechende genomische Biomarker zur Prognosebestimmung bei Blutkrebsbehandlungen 5Abaxis Reports Financial Performance for the First Quarter of Fiscal 2015 2Abaxis Reports Financial Performance for the First Quarter of Fiscal 2015 3Abaxis Reports Financial Performance for the First Quarter of Fiscal 2015 4Abaxis Reports Financial Performance for the First Quarter of Fiscal 2015 5Abaxis Reports Financial Performance for the First Quarter of Fiscal 2015 6Abaxis Reports Financial Performance for the First Quarter of Fiscal 2015 7Abaxis Reports Financial Performance for the First Quarter of Fiscal 2015 8Abaxis Reports Financial Performance for the First Quarter of Fiscal 2015 9Abaxis Reports Financial Performance for the First Quarter of Fiscal 2015 10Abaxis Reports Financial Performance for the First Quarter of Fiscal 2015 11Amgen Announces Webcast of 2014 Second Quarter Financial Results 2
... , NEW YORK, Oct. 16 Reportlinker.com announces ... in its catalogue. , Reportlinker Adds ... http://www.reportlinker.com/p0155102/Reportlinker-Adds-Allergan-Inc-PharmaVitae-Profile.html , Introduction , This ... Allergan in the Rx pharmaceutical sector. The profile ...
... NEW YORK, Oct. 16 Reportlinker.com ... report is available in its catalogue. ... Middle Eastern Pharmaceutical Market Outlook To ... landscape, growth opportunities , ...
Cached Medicine Technology:Reportlinker Adds Allergan Inc.: PharmaVitae Profile 2Reportlinker Adds Allergan Inc.: PharmaVitae Profile 3Reportlinker Adds Allergan Inc.: PharmaVitae Profile 4Reportlinker Adds Allergan Inc.: PharmaVitae Profile 5Reportlinker Adds Allergan Inc.: PharmaVitae Profile 6Reportlinker Adds The Middle Eastern Pharmaceutical Market Outlook To 2014: Policy environment, market structure, competitive landscape, growth opportunities 2Reportlinker Adds The Middle Eastern Pharmaceutical Market Outlook To 2014: Policy environment, market structure, competitive landscape, growth opportunities 3Reportlinker Adds The Middle Eastern Pharmaceutical Market Outlook To 2014: Policy environment, market structure, competitive landscape, growth opportunities 4Reportlinker Adds The Middle Eastern Pharmaceutical Market Outlook To 2014: Policy environment, market structure, competitive landscape, growth opportunities 5Reportlinker Adds The Middle Eastern Pharmaceutical Market Outlook To 2014: Policy environment, market structure, competitive landscape, growth opportunities 6Reportlinker Adds The Middle Eastern Pharmaceutical Market Outlook To 2014: Policy environment, market structure, competitive landscape, growth opportunities 7Reportlinker Adds The Middle Eastern Pharmaceutical Market Outlook To 2014: Policy environment, market structure, competitive landscape, growth opportunities 8Reportlinker Adds The Middle Eastern Pharmaceutical Market Outlook To 2014: Policy environment, market structure, competitive landscape, growth opportunities 9Reportlinker Adds The Middle Eastern Pharmaceutical Market Outlook To 2014: Policy environment, market structure, competitive landscape, growth opportunities 10Reportlinker Adds The Middle Eastern Pharmaceutical Market Outlook To 2014: Policy environment, market structure, competitive landscape, growth opportunities 11
(Date:7/25/2014)... July 25, 2014 As the category creator ... Xoçai is to transform and improve individual lives ... Adam Paul Green a successful Austin, Texas based ... at the end of the July to promote the up ... September 2014. , Eric Worre has been a leader in ...
(Date:7/25/2014)... At World T.E.A.M. Sports’ Adventure Team ... developmentally-disabled teens and young adults discovered that outdoor sporting ... and hiking can be challenging. , The third-year event, ... Chesapeake and Ohio Canal National Historical Park , included ... able-bodied. Under slightly overcast skies and temperatures in the ...
(Date:7/24/2014)... iFitDress.com, a renowned wedding dress manufacturer and retailer, ... party dresses . According to the company’s marketing specialist, ... at discounted prices, up to 59% off. The special ... , Most of the casual party dresses provided ... are popular for special designs, delicate craftsmanship and affordable ...
(Date:7/24/2014)... (PRWEB) July 25, 2014 A few ... Championships but the incredible high jump by Inika McPherson ... this past June, the USATF National Championships hosted the ... Zensah® athlete, Inika McPherson, won US Nationals with the ... new World Record for the biggest height over head ...
(Date:7/24/2014)... tumors, exposure to dim light at night made the ... to data published in Cancer Research , a ... negative effects of dim light exposure on tamoxifen treatment ... the night. , "Resistance to tamoxifen is a growing ... Steven M. Hill, PhD, professor of structural and cellular ...
Breaking Medicine News(10 mins):Health News:Austin, Texas Based "Xocai Activ Drink" Author, Adam Paul Green, to Visit Niigata Japan to Promote mxicorp.com/company/igc Eric Worre Speaking Engagement 2Health News:Austin, Texas Based "Xocai Activ Drink" Author, Adam Paul Green, to Visit Niigata Japan to Promote mxicorp.com/company/igc Eric Worre Speaking Engagement 3Health News:Austin, Texas Based "Xocai Activ Drink" Author, Adam Paul Green, to Visit Niigata Japan to Promote mxicorp.com/company/igc Eric Worre Speaking Engagement 4Health News:DC Adventure Team Challenge Thrills Developmentally-Disabled Participants 2Health News:DC Adventure Team Challenge Thrills Developmentally-Disabled Participants 3Health News:2014 Casual Party Dresses for Chic Ladies Now at iFitDress.com 2Health News:Setting A New High Jump World Record In Zensah® Compression 2Health News:Setting A New High Jump World Record In Zensah® Compression 3Health News:Exposure to dim light at night may make breast cancers resistant to tamoxifen 2
... SAN FRANCISCO, March 27 /PRNewswire/-- CVCTA Education, the ... introduced a new education,program that helps physicians reduce ... (CTA). When properly performed, radiation doses during CTA,are ... amount that has been attributed,to creating a health ...
... The following statement was,issued today by the law firm of ... given that a class action lawsuit was filed in the,United ... all purchasers of securities of NeuroMetrix Inc. (Nasdaq: NURO ... 6,2007, inclusive (the "Class Period")., If you wish to ...
... the American Association for Dental Research, convening this week ... scientists will be part of the Distinguished Lecture Series. ... will feature a Distinguished Lecture designed to interest delegates ... the Stemmons Ballroom at the Hilton Anatole Hotel., ...
... keynote presentations, symposia, and workshops that will anchor the ... Research, convening April 2 at the Hilton Anatole Hotel. ... , Optimizing the Survival of Ceramic ... Scherrer (University of Geneva, Switzerland), 3:15 p.m., Grand Ballroom ...
... most believed,they were not pregnant at the time ... each case., HARRISBURG, Pa., March 27 ... cases reported to the,Pennsylvania Patient Safety Authority in ... not pregnant, according to analysis published in the,Authority,s ...
... GPRO ) announced today that the Company will ... of Molecular Diagnostics Roundtable,Conference" in New York on April ... is scheduled to be webcast live and may be ... Gen-Probe,s website,at http://www.gen-probe.com . The webcast will be ...
Cached Medicine News:Health News:CVCTA Education Announces New LOW DOSE Initiative for CT Angiograms 2Health News:Shareholder Class Action Filed Against NeuroMetrix Inc. by The Law Firm of Schiffrin Barroway Topaz & Kessler, LLP 2Health News:Shareholder Class Action Filed Against NeuroMetrix Inc. by The Law Firm of Schiffrin Barroway Topaz & Kessler, LLP 3Health News:Shareholder Class Action Filed Against NeuroMetrix Inc. by The Law Firm of Schiffrin Barroway Topaz & Kessler, LLP 4Health News:Eminent scientists to lecture in Dallas 2Health News:Eminent scientists to lecture in Dallas 3Health News:Keynoters, symposia, workshops highlight dental research meeting 2Health News:Keynoters, symposia, workshops highlight dental research meeting 3Health News:Keynoters, symposia, workshops highlight dental research meeting 4Health News:Pennsylvania Patient Safety Authority Releases March Advisory Highlighting Communication Issues That Affect Patient Safety 2Health News:Pennsylvania Patient Safety Authority Releases March Advisory Highlighting Communication Issues That Affect Patient Safety 3Health News:Pennsylvania Patient Safety Authority Releases March Advisory Highlighting Communication Issues That Affect Patient Safety 4Health News:Gen-Probe to Webcast Presentation at Leerink Swann Molecular Diagnostics Conference 2
... national reference laboratory and a worldwide leader ... offers an extensive test menu of highly ... and anatomic pathology. Owned by the University ... than half of the nation's university teaching ...
... Laboratories is a national reference laboratory and ... and development. ARUP offers an extensive test ... tests in clinical and anatomic pathology. Owned ... clients include more than half of the ...
... national reference laboratory and a worldwide leader ... offers an extensive test menu of highly ... and anatomic pathology. Owned by the University ... than half of the nation's university teaching ...
... ARUP Laboratories is a national reference ... laboratory research and development. ARUP offers an ... unique medical tests in clinical and anatomic ... ARUP Laboratories' clients include more than half ...
Medicine Products: